Managers / Q3 2025
Kinnevik AB (publ)
CIK 0001766574 · SKEPPSBRON 18, STOCKHOLM, SE-103 13 · 46 8 526 000 00
Summary
Kinnevik AB (Publ) reported $66M in U.S.-listed holdings across 1 positions for Q3 2025.
The portfolio is heavily concentrated: RXRX alone accounts for 100.0% of reported value.
The book was largely unchanged from Q2 2025.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $66M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| RXRXRecursion Pharmaceuticals, Inc. | HELD | +0 | 13.43M | −$2M | $66M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | RXRXRecursion Pharmaceuticals, Inc.history → | CL A | 100.00% | $66M | 13.43M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $66M | 1 | Nov 4, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $68M | 1 | Aug 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $71M | 1 | Apr 28, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $80M | 1 | Jan 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $78M | 1 | Oct 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $89M | 1 | Jul 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $104M | 1 | Apr 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $103M | 1 | Feb 2, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $80M | 1 | Oct 6, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $78M | 1 | Jul 25, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $75M | 2 | Apr 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $177M | 3 | Feb 1, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $119M | 2 | Oct 25, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $176M | 2 | Aug 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $479M | 2 | May 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $779M | 2 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- Invik S.A.028-22172
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.